Zoster Vaccine, Live

BIOLOGICAL5 trials

Sponsors

Merck Sharp & Dohme LLC, Ab&B Bio-tech Co., Ltd.JS

Conditions

Herpes ZosterHerpes Zoster VaccineShinglesVaricella-zoster Vaccine

Phase 1

Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older

Active, not recruitingNCT06851832

Ab&B Bio-tech Co., Ltd.JSHerpes Zoster, Herpes Zoster Vaccine

Start: 2025-02-16End: 2028-09-16Target: 960Updated: 2026-03-31

Phase 2

ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)

CompletedNCT00546819

Merck Sharp & Dohme LLCHerpes Zoster

Start: 2007-10-31End: 2010-08-31Updated: 2017-04-12

Phase 3

Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)

CompletedNCT01245751

Merck Sharp & Dohme LLCHerpes Zoster, Varicella-zoster Vaccine

Start: 2011-04-30End: 2015-05-31Updated: 2017-04-12

Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)

CompletedNCT01505647

Merck Sharp & Dohme LLCHerpes Zoster, Shingles

Start: 2012-04-30End: 2012-11-30Updated: 2017-04-12

Phase 4

ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)

CompletedNCT00550745

Merck Sharp & Dohme LLCHerpes Zoster

Start: 2007-09-30End: 2009-01-31Updated: 2017-04-12

Related Papers

Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults

The Journal of Infectious Diseases2015-10-0971 citations